Exploring the Novel Therapeutic Potential of N-acetylcysteine in Depression,Bipolar Disorders and Anxiety

Introduction

N-acetylcysteine (NAC) is a sulfhydryl-containing drug that was first prescribed for medicinal purposes in 1967. It was initially patented in 1960. ¹ Since 1969, NAC has been utilized clinically in cystic fibrosis, ² and its application has grown to encompass chronic obstructive pulmonary disease and acetaminophen overdose; its clinical significance continues to grow. The World Health Organization (WHO) and the Food and Drug Administration (FDA) have both designated NAC as an essential medication. ³ NAC is typically sold as an over-the-counter nutritional supplement with antioxidant qualities in several countries, including the USA, Canada, and Australia. ⁴ Clinical applications of NAC have grown in tandem with our growing understanding of its activity. Apart from its well-established medicinal applications, there has been a surge in interest lately in the application of NAC in the management of neuropsychiatric disorders such as anxiety, depression, and bipolar disorder. ⁵

NAC is a possible adjunctive treatment option for people with psychiatric disorders since it is a precursor to the antioxidant glutathione and has been demonstrated to control glutamate levels, reduce inflammation, and improve overall brain function. ⁶ The use of NAC in psychiatric diseases has been the subject of numerous research, which has highlighted both its neuroprotective and neurotrophic qualities. The potential effectiveness of NAC in treating diseases such as bipolar disorder, schizophrenia, OCD, drug use disorders, and generalized anxiety disorder has been studied. ² Studies have demonstrated that NAC supplementation may benefit people with psychiatric disorders by lowering symptoms, enhancing cognitive function, and improving treatment outcomes. ⁷ The NAC complex and its multiple mechanisms of action in psychiatric diseases include antioxidant effects, modulation of inflammation, improvement of neuroplasticity, and regulation of glutamate neurotransmission. ⁸ NAC is a viable option for the treatment of several psychiatric conditions due to its diverse neuroprotective qualities.

Millions of individuals worldwide suffer from depression, and while many are helped by modern anti-depressants, a sizeable fraction either do not get better or have unbearable side effects. NAC possesses anti-inflammatory and antioxidant qualities, which have demonstrated potential therapeutic benefits in treating depression. ⁹ Another difficult psychiatric illness that needs appropriate long-term therapy is bipolar disorder. Mood stabilizers are frequently used to treat repeated manic and depressive episodes that bipolar disorder sufferers experience. These medications may not always work well and may have negative consequences. As an additional or alternative treatment for bipolar disorder, NAC has demonstrated promise. This may lessen the intensity and occurrence of manic and depressive episodes by regulating glutamatergic circuits that are dysregulated in the illness. ¹⁰ Among the most prevalent mental health issues globally are anxiety disorders, for which benzodiazepines and selective serotonin reuptake inhibitors (SSRIs) may not be the best or most appropriate treatments for some individuals. Anxiolytic effects of NAC have been demonstrated in preclinical and clinical investigations. It could function by lowering oxidative stress and modifying glutamatergic neurotransmission. ¹¹ This review article aims to provide a comprehensive overview of the current evidence supporting the use of NAC in the management of depression, bipolar disorder, and anxiety, including recent clinical studies evaluating its effectiveness and safety in patients with these conditions. By synthesizing and critically evaluating the existing literature, this review seeks to shed light on the potential therapeutic applications of NAC in addressing the unmet needs of individuals suffering from mood and anxiety disorders.

Methodology

Books were reviewed and medical and scientific literature found in MEDLINE and PubMed were analyzed for an assessment of NAC’s therapeutic potential in psychiatric illnesses such as anxiety, depression, and bipolar disorder. Using the key terms “NAC,” “N-acetyl-l-cysteine,” “psychiatric disorders,” “anxiety,” “depression,” “bipolar disorder,” and other terms unique to each disorder, literature searches were conducted. A review of articles released in the past 20 years (until December 2022) was conducted, focusing on human research with a preference for meta-analyses or randomized control trials (RCTs). When available, preclinical or animal research was also included.

Mechanism of Action

NAC is a thiol that functions as an acetylated precursor of the amino acid l-cysteine. By giving one or two electrons, it can function as a nucleotide or as a radical reducer.^{12, 13} Its molecular structure, which consists of an amino group (NH₂) connected to a functional sulfhydryl group (–SH) and acetyl group (–COCH₃), is what allows it to perform metabolic activities that include direct and indirect antioxidant and mucolytic effects (Figure 1). ¹⁴ Because of its free thiol group’s capacity to react with reactive oxygen and nitrogen compounds (RONS), NAC has direct antioxidant action. ¹⁵ Under experimental conditions, NAC rapidly reacts with the reduced and protonated form of nitric oxide (•NE), nitroxyl (HNO), hydroxyl radical (•OH), nitrogen dioxide (•NO₂), carbon trioxide ion (CO₃•−), and thiyl radical (RS•). Superoxide (O₂•−), hydrogen peroxide (H₂O₂), and peroxynitrite (ONOO−) radical anion reactions are comparatively slow. ¹⁶

OPEN IN VIEWER

Figure 1.

Source: Aldini et al.28

There are questions regarding the significance of NAC’s direct antioxidant capacity against RONS under physiological conditions because of its generally lower reaction rate when compared to other enzymatic and non-enzymatic antioxidants and other substrates, especially when taking into account other factors such as its endogenous concentration and location (cellular or extracellular). ¹⁶ NAC may, however, have direct antioxidant action against some oxygen species, such as NO₂ and hypohaloacids (HOX), depending on its relative content of other thiols. ¹⁶ Experimental research indicates that NAC, like other thiols, can bind with its free thiol to active redox metal ions, including heavy metals such as lead (Pb²⁺) and mercury (Hg²⁺) and transition metals such as copper (Cu²⁺) and iron (Fe³⁺), forming complexes that the body can easily eliminate. ¹³ There have been few clinical trials examining NAC’s chelating abilities, even though it can lower metal ion levels in toxicity. ¹⁷ The potential of NAC as a chelating agent remains to be determined, as does the extent to which its effects as an indirect antioxidant stems from its ability to enhance the intracellular tripeptide (l-γ-glutamyl-l-cysteinyl glycine) that contains cysteines called GSH (glutathione). ¹⁸

The most prevalent non-protein thiol in the body, GSH is one of the most significant antioxidants that keep cells in their proper redox state. Apart from directly reacting with reactive chemicals, GSH also serves as a cofactor or substrate for other antioxidants. ¹⁶ Because cysteine has a lower intracellular concentration, it acts as a rate-limiting factor for the manufacture of GSH. This characteristic clarifies NAC’s function as a prodrug of intracellular GSH and cysteine. ¹⁹ Because NAC can raise intracellular cysteine levels, which raises GSH levels, it is significant as a potent antioxidant. ¹⁹

As a result, NAC is one of the most essential drugs to prevent oxidative stress–induced damage in diseases linked with xenobiotic poisoning, such as paracetamol or GSH insufficiency. ¹³ Furthermore, NAC can break down thiol proteins, including cysteinylated extracellular proteins, which release free thiols, which are more potent antioxidants and improve the synthesis of GSH. NAC’s reducing capacity is connected to another process that contributes to its indirect antioxidant activity. Low molecular weight (LMW) thiol ubiquitous groups and decreased protein sulfhydryl groups implicated in redox state modulation can be restored by NAC. ²⁰ The ability of NAC to alter protein structure and/or function has also been reported in experimental studies. ²¹ This includes changes in the tumor necrosis factor (TNF-α) receptor’s affinity for cytokines, reduction of angiotensin II receptor binding in vascular smooth muscle cells, and reduction of transforming growth factor beta 1 (TGF-β1) upon binding to beta-glucan of the transforming growth factor receptor type III (TβRIII).^{22, 23} Lastly, NAC also reduces inflammation by blocking nuclear factor kappa (NF-κB), the light chain enhancer of activated B-cells, which is essential for the inflammatory cascade and the immunological response linked to the oxidative response. NAC suppresses nuclear activation and translocation of NF-κB, a transcription factor that controls the expression of genes that promote inflammation. ²⁴ It has been demonstrated that NAC prevents lipopolysaccharide-activated macrophages from releasing the inflammatory cytokines TNF-α, interleukin (IL)-1β, and IL-6. ²⁵

Potential Mechanism of N-acetylcysteine in Psychiatric Disorders

NAC has a complex mode of action that includes anti-inflammatory effects, oxidative stress reduction, and glutamate modulation. These outcomes add to the medication’s therapeutic advantages in treating a range of psychiatric illnesses. The following are some important pathways via which NAC works in mental illnesses:

Modulation of glutamatergic neurotransmission: Glutathione is a powerful antioxidant that is essential for preserving redox balance and shielding neurons from oxidative damage. NAC functions as a precursor to glutathione. ⁶ NAC can influence glutamatergic neurotransmission by elevating glutathione levels, namely, through controlling the cystine/glutamate antiporter system (xC−) and reestablishing the equilibrium between extracellular glutamate and cystine levels in the brain. This may lessen the neuroinflammation and excitotoxicity linked to mental illnesses. ⁶

It has been established that NAC may be used as a therapy approach for mental illnesses such as bipolar disorder, anxiety, and depression. The method by which NAC modulates the symptoms of psychiatric diseases is explained by its influence on decreasing oxidative or inflammatory cytokines. ²⁷ According to a review based on available data, disruptions in brain energy metabolism, mitochondrial functions, and redox balance linked to environmental and genetic factors are responsible for the genesis and progression of psychiatric disorders. ²⁸ These disruptions are not only clinically linked to disease-specific symptoms but also alter an individual’s circadian rhythm and metabolic rate. Antioxidant activity, decreased cytokine activity, modulation of dopamine release, reversal of mitochondrial dysfunction, reduction of apoptosis and ferroptosis, anti-inflammatory effects, increased neurogenesis, and increased glutamate release are just a few of the numerous significant roles that NAC plays. ²⁹

Its antioxidant impact, which is mediated through multiple mechanisms, is arguably the most significant of them in the treatment of psychiatric diseases. By promoting glutathione synthesis, elevating glutathione S-transferase activity, scavenging free radicals, and activating group II metabotropic glutamate receptors to decrease glutamate turnover, NAC functions as an antioxidant. ³⁰ The primary endogenous antioxidant in the brain is glutathione. Glutathione in the brain is increased when l-cysteine levels are raised with NAC administration, as this compound’s rate of formation is dependent on l-cysteine availability. ¹⁶ Antioxidants lessen oxidative stress, which has a role in the etiology of numerous mental illnesses. ¹⁸

An imbalance between tissue redox defense and ROS, including superoxide, peroxynitrite, and hydrogen peroxide, is known as oxidative stress. Increased ROS, compromised antioxidant defenses, or unrepaired oxidative damage could be the cause. ³¹ ROS induce DNA changes, peroxidation of cellular lipids, and inactivation of significant respiratory chain enzymes. ³¹ Superoxide dismutase, glutathione reductase, and peroxidase are examples of antioxidant enzymes that convert ROS into less harmful molecules and shield the brain from oxidative stress–related damage. ³¹ By boosting the production and storage of glutathione disulfide, which results in export and extracellular hydrolysis, protein S-glutathionylation, and the development of glutathione-dependent humans, severe long-term oxidative stress can cause glutathione depletion. ³² It has been demonstrated that NAC can prevent mitochondrial malfunction, which is linked to oxidative stress. ³³

Role of N-acetylcysteine in Psychiatric Diseases

Discussion

NAC has demonstrated encouraging therapeutic benefits in a range of psychiatric disorders by reducing oxidative stress, exhibiting anti-inflammatory properties, modulating glutamatergic neurotransmission, and modifying neurotransmitter systems, all of which help to alleviate symptoms and neuropathologies. ⁶ According to research, NAC helps lessen symptoms of anxiety, bipolar disorder, depression, obsessive-compulsive disorder, schizophrenia, and drug use disorders. ²⁶ Additionally, it has been demonstrated to improve cognitive performance in patients with certain psychiatric diseases and increase the efficacy of traditional treatments. ⁵⁹

When treating psychiatric diseases, the recommended daily amount of NAC is usually divided into two or three doses, ranging from 1,200 to 3,600 mg. Depending on an individual’s response and the severity of the symptoms, higher doses can be required in some situations. ⁶ Preclinical and clinical research on depression, anxiety, and bipolar disorder have demonstrated the behavioral efficacy of NAC. It has been demonstrated to lessen obsessive behaviors, elevate mood, and lessen anxiety. ⁶⁰

The effectiveness of NAC as an adjuvant treatment for patients with major depressive illness was examined in a 2019 study by Berk et al. The findings demonstrated that these individuals’ overall functioning and depressive symptoms were both improved by NAC supplementation. ⁶¹ Supplementing with NAC reduced anxiety symptoms in patients with generalized anxiety disorder, according to a randomized controlled experiment conducted by Sarris et al. According to the study, those taking NAC experienced much lower levels of stress and anxiety than the placebo group. ⁶²

Overall, these recent clinical studies demonstrate the potential effectiveness of NAC as an adjunctive treatment in patients with depression, anxiety, and bipolar disorders. Further research is needed to confirm these findings and elucidate the underlying mechanisms of action of NAC in these psychiatric conditions. Based on recent studies, there is strong evidence that NAC is a novel and successful treatment for anxiety, bipolar disorder, and depression. More research is required because many of the RCTs and preclinical studies that have been discussed have provided only basic information about the efficacy of NAC in therapy. On the other hand, NAC seems to be a promising therapeutic target and provides a therapeutic option in a field where other treatments are inadequate or ineffective. Evidence points to NAC’s potential anti-depressant benefits, which may stem from its anti-inflammatory and antioxidant qualities as well as how it affects glutamate and dopamine neurotransmission. ⁹ Because of its capacity to control glutamatergic pathways and possibly lessen the severity and frequency of manic and depressive episodes, NAC is a viable alternative or complementary treatment for bipolar illness. ¹⁰ Furthermore, NAC has demonstrated anxiolytic benefits, potentially through lowering oxidative stress and modifying glutamatergic neurotransmission. ¹¹ Even if the data is encouraging, more extensive and well-designed research is still required to fully understand the clinical effectiveness of NAC in these conditions. It is noteworthy that a lot of recent research exclusively examines NAC as an adjuvant treatment. NAC monotherapy clinical trials are necessary to accurately ascertain the drug’s therapeutic potential. While oxidative stress appears to be a fairly non-specific finding in several psychopathologies, glutamate dysregulation and inflammatory pathways have also been widely reported. ¹¹

NAC’s apparent lack of specificity in early studies is intriguing and suggests that it may target pathways common to different diseases. It is possible that some places are more beneficial than others as the body of evidence grows. Because glutamate, the most widely distributed neurotransmitter, interacts with other neurotransmitters, such as serotonin and dopamine, people suffering from diseases such as bipolar disorder and depression may benefit from indirect manipulation of these pathways through modifications in glutamatergic activity. ¹² Since oxidative stress is altered in the majority of these conditions, there may be a common link to therapy efficacy. In a similar vein, the advantages from NAC administration might be attributed to the regulation of inflammatory pathways. Most research has focused on the connection between inflammation and depression. ⁶³ Further research is necessary to determine the ideal dosage and long-term safety profile of NAC. Furthermore, the precise dosage of NAC is yet to be established. Studies on dose finding may demonstrate the same efficacy at lower doses or increased efficacy at higher levels. Research is necessary, nonetheless, considering the great safety profile of NAC and the possible advantages demonstrated in a number of clinical trials and uncontrolled studies. NAC is used to treat anxiety, bipolar illness, and depression. ⁵⁷ This improbable therapeutic instrument presents novel pathways as potential targets for therapy. This opens the door for the creation of additional logical, hypothesis-driven therapies. NAC’s apparent safety, tolerability, affordability, and accessibility all contribute to its allure.

Conclusion

The potential therapeutic uses of NAC in the field of psychiatry are highlighted in this review study. An affordable and easily accessible substance, NAC has demonstrated encouraging effects in treating a number of mental illnesses, such as anxiety, bipolar disorder, and depression. To enhance patient outcomes, however, more funds and resources for research should be invested in examining NAC in larger clinical trials. This will give clinicians access to evidence-based therapy alternatives. To sum up, NAC exhibits potential as a therapeutic agent for psychiatric problems such as anxiety, bipolar disorder, and depression. We can improve our understanding of the efficacy and safety of this medication by performing thorough clinical studies and broadening our understanding of its mechanisms of action. This will ultimately lead to better management and treatment of patients with psychiatric disorders.

Abbreviations

NAC: N-acetylcysteine; FDA: Food and Drug Administration; WHO: World Health Organization; RCT: Randomized controlled trial; GSH: Glutathione; TNF-α: Tumor necrosis factor-alpha; TGF-β1: Transforming growth factor beta 1; TβRIII: Transforming growth factor receptor betaglycan; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; MADRS: Montgomery–Åsberg Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation-Range of Impaired Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Interview Clinical Evaluation from the Longitudinal Interval Follow-up Evaluation; CGI-S: Clinical Global Impression Scales-Severity; SOFAS: Social and Occupational Functioning Assessment Scale; BD: Bipolar disorder; MDD: Major depressive disorders